

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

PE anti-mouse CD69

RRID:AB_313110

Type: Antibody

Proper Citation

BioLegend Cat# 104507, RRID:AB_313110

Antibody Information

URL: http://antibodyregistry.org/AB_313110

Proper Citation: BioLegend Cat# 104507, RRID:AB_313110

Target Antigen: CD69

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD69

Description: This monoclonal targets CD69

Target Organism: mouse

Clone ID: Clone H1.2F3

Antibody ID: AB_313110

Vendor: BioLegend

Catalog Number: 104507

Alternative Catalog Numbers: 104508

Record Creation Time: 20250819T215102+0000

Record Last Update: 20250820T001801+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD69.

No alerts have been found for PE anti-mouse CD69.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. Cancer immunology research, 14(1), 122.

Yang S, et al. (2026) Oat-?-glucan potentiates anti-PD-1 efficacy through Faecalibacterium prausnitzii-derived butyrate and indole-3-propionic acid. Cell host & microbe, 34(7), 1333.

Duguid A, et al. (2026) miR-93-mediated PTEN suppression and CNS-specific T cell exhaustion shape the leukemia niche in infant KMT2A::AFF1+ B-ALL. Cell reports, 45(5), 117353.

Janas PP, et al. (2025) Epithelial Memory After Respiratory Viral Infection in Mice Results in Prolonged Enhancement of Antigen Presentation. Allergy, 80(9), 2501.

Lange T, et al. (2025) Systemic EP4 receptor agonist and Arginase-1 therapy in a murine model of chronic asthma and influenza virus-induced asthma exacerbation. British journal of pharmacology, 182(12), 2803.

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. Cell reports. Medicine, 6(12), 102510.

Young RE, et al. (2025) Disruption of E-cadherin in the airway led to dysplastic stressed cells and asthma-like phenotypes. Developmental cell.

Zhao HY, et al. (2025) An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment. Cell chemical biology, 32(2), 280.

Barandun N, et al. (2025) Targeted localization of the mother centrosome in CD8+ T cells undergoing asymmetric cell division promotes memory formation. Cell reports, 44(1), 115127.

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. Cancer cell, 43(7), 1227.

Xing Y, et al. (2025) Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer. *Developmental cell*.

Zhang K, et al. (2024) The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model. *International journal of molecular sciences*, 25(3).

Monasterio G, et al. (2024) A versatile tissue-rolling technique for spatial-omics analyses of the entire murine gastrointestinal tract. *Nature protocols*, 19(10), 3085.

Sanchez GM, et al. (2024) Aberrant zonal recycling of germinal center B cells impairs appropriate selection in lupus. *Cell reports*, 43(11), 114978.

Ping Y, et al. (2024) PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8⁺ T cell ferroptosis. *Immunity*, 57(9), 2122.

Ulibarri MR, et al. (2024) Epithelial organoid supports resident memory CD8 T cell differentiation. *Cell reports*, 43(8), 114621.

Zhou Z, et al. (2024) Rebalancing TGF- β /PGE2 breaks RT-induced immunosuppressive barriers by enhancing tumor-infiltrated dendritic cell homing. *International journal of biological sciences*, 20(1), 367.

Sekiya T, et al. (2024) Tonic TCR and IL-1 β signaling mediate phenotypic alterations of naive CD4⁺ T cells. *Cell reports*, 43(3), 113954.

Zhang Z, et al. (2024) Malic enzyme 2 maintains metabolic state and anti-tumor immunity of CD8⁺ T cells. *Molecular cell*, 84(17), 3354.

Park CS, et al. (2024) Fam49b dampens TCR signal strength to regulate survival of positively selected thymocytes and peripheral T cells. *eLife*, 13.